Abstract
The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Current Pharmaceutical Design
Title:Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Volume: 20 Issue: 14
Author(s): Sho-ichi Yamagishi and Takanori Matsui
Affiliation:
Keywords: Atherosclerosis, cardiometabolic disorders, oxidative stress, PEDF.
Abstract: The metabolic syndrome is strongly associated with insulin resistance and visceral obesity and consists of a constellation of factors such as diabetes, hypertension, dyslipidemia and non-alcoholic steatohepatits, which could in concert increase the risk for cardiovascular diseases (CVD). CVD, including myocardial infarction and stroke, is one of the leading causes of morbidity and mortality in the developed countries. Atherothrombosis, characterized by atherosclerotic plaque disruption and subsequent thrombus formation, contributes to the pathogenesis of CVD. Although therapeutic strategy for CVD has been progressed with anti-platelet and anti-thrombotic therapy, statins, and inhibitors of renin-angiotensin system, current therapeutic options may have therapeutic limitations because a substantial number of patients still experience CVD. Therefore, to develop novel therapeutic strategies that specifically target CVD is intensely desired. We and the others, have recently found that pigment epithelium-derived factor (PEDF), one of the serpins with neuronal differentiative activity, has insulin-sensitizing actions in the liver and adipose tissues, and exerts anti-inflammatory, anti-thrombogenic and vasculoprotective properties in vivo, thereby playing a protective role against the development and progression of the metabolic syndrome and CVD. In addition, serum levels of PEDF have been shown to increase in patients with visceral obesity, insulin resistance, diabetes, chronic kidney disease and CVD, thus being a novel biomarker of various cardiometabolic disorders. This paper discusses not only the role of PEDF, but also the clinical utility of measuring its levels in patients with various cardiometabolic disorders.
Export Options
About this article
Cite this article as:
Yamagishi Sho-ichi and Matsui Takanori, Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990473
DOI https://dx.doi.org/10.2174/13816128113199990473 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelium: A Target for Harmful Actions of Metals
Current Hypertension Reviews HGF as Angiogenic Factor and Therapeutic Approach
Current Signal Transduction Therapy Ibopamine Stimulates α-Adrenergic Receptors and D1 Dopaminergic Receptors in the Eye
Current Drug Therapy Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Editorial [Hot topic: The Challenge of Prescribing Drugs in Older People (Guest Editors: Fabrizia Lattanzio and Andrea Corsonello)]
Current Drug Metabolism A Possible Target of Antioxidative Therapy for Diabetic Vascular Complications-Vascular NAD(P)H Oxidase
Current Medicinal Chemistry Novel Tyrosine Kinase Inhibitors in the Treatment of Cancer
Current Drug Targets Oxidative Stress in Cerebral Small Vessel Disease Dizziness Patients, Basally and After Polyphenol Compound Supplementation
Current Molecular Medicine Do Histamine receptor 3 antagonists have a place in the therapy for schizophrenia?
Current Pharmaceutical Design Short-term RR-Interval Power Spectral Analysis as a New Tool to Stratify the Risk of Sudden Death in Various Cardiovascular Conditions
Vascular Disease Prevention (Discontinued) Functional, Genetic and Biochemical Biomarkers of Peripheral Arterial Disease
Current Medicinal Chemistry Recent Advances in the Synthesis of 1,3-Azoles
Current Topics in Medicinal Chemistry The Neuropathology of Vascular Disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)
Current Alzheimer Research Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry The Endothelial-Mesenchymal Transition (EndMT) and Tissue Regeneration
Current Stem Cell Research & Therapy Preterm Labour: An Overview of Current and Emerging Therapeutics
Current Medicinal Chemistry Polydeoxyribonucleotide (PDRN): A Safe Approach to Induce Therapeutic Angiogenesis in Peripheral Artery Occlusive Disease and in Diabetic Foot Ulcers
Cardiovascular & Hematological Agents in Medicinal Chemistry Inhibitor Design for SARS Coronavirus Main Protease Based on “Distorted Key Theory”
Medicinal Chemistry Editorial: [Aliskiren/Amlodipine Single-Pill Combinations: More Evidence in Favour of Combination Formulations for the Treatment of Hypertension]
Current Vascular Pharmacology Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued)